

requirements of 35 U.S.C. 209 and 37 CFR part 404.

Complete applications for a license in the prospective field of use that are filed in response to this notice will be treated as objections to the grant of the contemplated Exclusive Commercialization Patent License Agreement. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the *Freedom of Information Act*, 5 U.S.C. 552.

Dated: September 21, 2016.

**Richard U. Rodriguez,**

*Associate Director, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2016-23134 Filed 9-23-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **Prospective Grant of Start-Up Exclusive Evaluation Patent License: Development of Autologous Tumor-reactive T Cells Isolated From Peripheral Blood for the Treatment of Metastatic Follicular Thyroid Cancer and Metastatic Soft Tissue Sarcomas**

**AGENCY:** National Institutes of Health.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-up Exclusive Evaluation Patent License to MedGene Therapeutics, Inc. ("MedGene") located in Bethesda, MD to practice the inventions embodied in the patent applications listed Supplementary Information section of this notice.

**DATES:** Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before October 11, 2016 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Start-up Exclusive Evaluation Patent License should be directed to: Andrew Burke, Ph.D., Licensing and Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville, MD 20850-9702 Telephone: (240) 276-5530; Facsimile: (240) 276-5504; Email: [andy.burke@nih.gov](mailto:andy.burke@nih.gov).

**SUPPLEMENTARY INFORMATION:** United States Provisional Patent Application

No. 61/771,251 filed March 1, 2013, entitled "Methods of Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood" [HHS Reference No. E-085-2013/0-US-01]; and PCT Application No. PCT/US2013/038813 filed April 30, 2013 entitled "Methods of Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood" [HHS Reference No. E-085-2013/0-PCT-02] (and U.S. and foreign patent applications claiming priority to the aforementioned applications).

The patent rights in these inventions have been assigned to the government of the United States of America.

The prospective Start-up Exclusive Evaluation Patent License territory may be worldwide and the field of use may be limited to the development, manufacture and commercialization of autologous tumor-reactive peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of metastatic follicular thyroid cancer and metastatic soft tissue sarcomas in humans.

The present invention describes a method of selecting highly tumor-reactive T cells from autologous peripheral blood samples based on the expression of two specific T cell surface markers: Programmed cell death protein 1 (PD-1; CD279) and/or T cell Ig- and mucin-domain-containing molecule-3 (TIM-3). Following selection, isolated cells may be expanded and reinfused into the donor patient as part of an adoptive cell transfer therapeutic regimen. The disclosed method may be advantageous over existing approaches which rely on the isolation of T cells from tumor samples since it eliminates the cost and complications associated with tumor resection, as well as provides a T cell product for patients without resectable lesions.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective Start-up Exclusive Evaluation Patent License will be royalty bearing and the may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

Complete applications for a license in the prospective field of use that are timely filed in response to this notice will be treated as objections to the grant of the contemplated Start-up Exclusive Evaluation Patent License. Comments and objections submitted to this notice will not be made available for public

inspection and, to the extent permitted by law, will not be released under the *Freedom of Information Act*, 5 U.S.C. 552.

Dated: September 20, 2016.

**Richard U. Rodriguez,**

*Associate Director, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2016-23048 Filed 9-23-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **National Institute of Neurological Disorders and Stroke**

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of an Interagency Pain Research Coordinating Committee (IPRCC) meeting.

The meeting will feature invited speakers and discussions of committee business items including a progress report on implementation of the National Pain Strategy, updates on the Federal Pain Research Strategy and new pain initiatives.

The meeting will be open to the public and accessible by live webcast and conference call.

*Name of Committee:* Interagency Pain Research Coordinating Committee.

*Type of meeting:* Open Meeting.

*Date:* October 31, 2016.

*Time:* 8:30 a.m. to 5:00 p.m. \*Eastern Time\*—Approximate end time.

*Agenda:* The meeting will feature invited speakers and discussions of Committee business items including a progress report on implementation of the National Pain Strategy, updates on the Federal Pain Research Strategy and new pain initiatives.

*Place:* National Institutes of Health, Building 31C, 6th Floor, Room 10, 31 Center Drive, Bethesda, MD 20892.

*Cost:* The meeting is free and open to the public.

*Webcast Live:* <http://videocast.nih.gov/>.

*Deadlines:* Notification of intent to present oral comments: Monday, October 17, 2016, by 5:00 p.m. ET.

Submission of written/electronic statement for oral comments: Monday, October 24, 2016, by 5:00 p.m. ET.

Submission of written comments: Monday, October 24, 2016, by 5:00 p.m. ET.

*Access:* Medical Center Metro (Red Line). Visitor Information: <http://www.nih.gov/about/visitor/index.htm>.

*Contact Person:* Linda L. Porter, Ph.D., Pain Policy Advisor, Office of Pain Policy, Officer of the Director, National Institute of Neurological Disorders and Stroke, NIH, 31 Center Drive, Room 8A31, Bethesda, MD 20892, Phone: (301) 451-4460, Email: [Linda.Porter@nih.gov](mailto:Linda.Porter@nih.gov).

*Please Note:*

Any member of the public interested in presenting oral comments to the Committee must notify the Contact Person listed on this notice by 5:00 p.m. ET on Monday, October 17, 2016, with their request to present oral comments at the meeting. Interested individuals and representatives of organizations must submit a written/electronic copy of the oral statement/comments including a brief description of the organization represented by 5:00 p.m. ET on Thursday, October 24, 2016.

Statements submitted will become a part of the public record. Only one representative of an organization will be allowed to present oral comments on behalf of that organization, and presentations will be limited to three to five minutes per speaker, depending on number of speakers to be accommodated within the allotted time. Speakers will be assigned a time to speak in the order of the date and time when their request to speak is received, along with the required submission of the written/electronic statement by the specified deadline. If special accommodations are needed, please email the Contact Person listed above.

In addition, any interested person may submit written comments to the IPRCC prior to the meeting by sending the comments to the Contact Person listed on this notice by 5:00 p.m. ET, Monday, October 24, 2016. The comments should include the name and, when applicable, the business or professional affiliation of the interested person. All written comments received by the deadlines for both oral and written public comments will be provided to the IPRCC for their consideration and will become part of the public record.

The meeting will be open to the public and webcast live on the Internet. If you experience any technical problems with the webcast, please call the NIH IT Service Desk at (301) 496-4357, toll free (866) 319-4357, for webcast issues.

Individuals who participate in person or by using the web service and who need special assistance, such as captioning, should submit a request to the Contact Person listed on this notice at least seven days prior to the meeting.

As a part of security procedures, attendees should be prepared to present a photo ID during the security process to get on the NIH campus. For a full description, please see: <http://www.nih.gov/about/visitorsecurity.htm>.

Information about the IPRCC is available on the Web site: <http://iprcc.nih.gov/>.

Dated: September 20, 2016.

**Sylvia L. Neal,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016-23143 Filed 9-23-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HOMELAND SECURITY

### Coast Guard

[Docket No. USCG-2010-0164]

### National Boating Safety Advisory Council

**AGENCY:** Coast Guard, DHS.

**ACTION:** Notice of Federal Advisory Committee meeting.

**SUMMARY:** The National Boating Safety Advisory Council and its Subcommittees will meet on October 20, 21 and 22, 2016, in Arlington, VA, to discuss issues relating to recreational boating safety. These meetings will be open to the public.

**DATES:** The National Boating Safety Advisory Council will meet on Thursday, October 20, 2016, from 8:00 a.m. to 2:30 p.m. and on Saturday, October 22, 2016 from 9:00 a.m. to 12:00 p.m. The Boats and Associated Equipment Subcommittee will meet on October 20, 2016, from 2:45 p.m. to 5:00 p.m. The Prevention through People Subcommittee will meet on October 21, 2016, from 8:30 a.m. to 11:45 a.m. The Recreational Boating Safety Strategic Planning Subcommittee will meet on October 21, 2016, from 1:00 p.m. to 5:00 p.m. Please note that these meetings may conclude early if the National Boating Safety Advisory Council has completed all business.

**ADDRESSES:** All meetings will be held in the Ballroom of the Holiday Inn Arlington (<http://www.hiarlington.com>), 4610 N Fairfax Drive, Arlington, VA 22203.

For information on facilities or services for individuals with disabilities or to request special assistance at the meeting, contact the individual listed in the **FOR FURTHER INFORMATION CONTACT** section below as soon as possible.

**Instructions:** To facilitate public participation, we are inviting public comment on the issues to be considered by the Council as listed in the "Agenda" section below. Written comments for distribution to Council members must be submitted no later than October 1, 2016, if Council review is desired prior to the meeting. You must include "Department of Homeland Security" and the docket number USCG-2010-

0164. Written comments may also be submitted using the Federal eRulemaking Portal at <http://www.regulations.gov>. For technical difficulties, contact the individual listed in the **FOR FURTHER INFORMATION CONTACT** section below. Comments received will be posted without alteration at <http://www.regulations.gov>, including any personal information provided. You may review a Privacy Act notice regarding the Federal Docket Management System in the March 24, 2005, issue of the **Federal Register** (70 FR 15086).

**Docket Search:** For access to the docket to read documents or comments related to this notice, go to <http://www.regulations.gov> insert USCG-2010-0164 in the "Search" box, press Enter, then click the item you wish to view.

**FOR FURTHER INFORMATION CONTACT:** Mr. Jeff Ludwig, Alternate Designated Federal Officer of the National Boating Safety Advisory Council, telephone (202) 372-1061, or at [jeffrey.a.ludwig@uscg.mil](mailto:jeffrey.a.ludwig@uscg.mil).

**SUPPLEMENTARY INFORMATION:** Notice of this meeting is given under the *Federal Advisory Committee Act* (Title 5, U.S.C., Appendix). Congress established the National Boating Safety Advisory Council in the *Federal Boat Safety Act of 1971* (Pub. L. 92-75). The National Boating Safety Advisory Council currently operates under the authority of 46 U.S.C. 13110 and 46 U.S.C. 4302(c). The latter requires the Secretary of Homeland Security and the Commandant of the Coast Guard by delegation to consult with the National Boating Safety Advisory Council in prescribing regulations for recreational vessels and associated equipment and on other major safety matters.

### Meeting Agenda

The agenda for the National Boating Safety Advisory Council meeting is as follows:

*Thursday, October 20, 2016*

(1) Opening remarks and presentation of awards to outgoing members.

(2) Receipt and discussion of the following reports:

(a) Chief, Office of Auxiliary and Boating Safety, Update on the Coast Guard's implementation of National Boating Safety Advisory Council Resolutions and Recreational Boating Safety Program report.

(b) Alternate Designated Federal Officer's report concerning Council administrative and logistical matters.

(3) Presentations on the following:  
(a) Distracted Driving.